North Carolina Medicaid GLP-1 Coverage (2026): The Double-Reversal State — Covered (Aug 2024) → Terminated (Oct 2025) → Reinstated (Dec 2025), Wegovy Preferred, Most-Permissive Pathway in the 9-State Series

TL;DR — the double-reversal state

North Carolina Medicaid is the DOUBLE-REVERSAL state — the first and only program in our 9-state series whose chronic weight-management coverage pathway has completed an entire on-off-on cycle within 16 months. The trajectory is a documented historical record:

• August 1, 2024 — coverage added via State Plan Amendment TN 24-0032, approved by CMS.
• October 1, 2025 — coverage terminated by NC Medicaid due to a state-budget shortfall ($319 million gap, per NCDHHS Secretary Dev Sangvai).
• December 12, 2025 — coverage reinstated by direct gubernatorial directive.
• January 22, 2026 — NC Medicaid PDL Review Panel formally ratified the reinstatement.

As of the NC Medicaid Preferred Drug List effective January 1, 2026 (Revised 12.10.2025 Off Cycle Change), the new “WEIGHT MANAGEMENT AGENTS — GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimetics)” class lists Wegovy as Preferred and Saxenda and Zepbound as Non-Preferred. The operative clinical PA criteria revert to the August 1, 2024 document (PAG Submission 25J7).

NC is structurally more permissive than every other state in this 9-state series:

• Wegovy is Preferred for the chronic-weight-management indication — the only such PDL listing across all nine states surveyed.
• The MASH pathway includes F1 fibrosis, broader than the FDA Wegovy MASH label (F2/F3) and broader than Pennsylvania and Ohio.
• The Zepbound OSA pathway requires BMI > 30 (FDA label-aligned), more permissive than Pennsylvania’s BMI ≥ 35 floor.
• No lifetime treatment cap and a 12-month renewal cycle after the first 6-month approval.

At the same time, the NC State Health Plan (SHP) — a separate program covering approximately 740,000 state employees, retirees, and dependents — terminated weight-loss GLP-1 coverage by a 4-3 board vote in January 2024, effective April 1, 2024, and that termination remains in effect as of 2026-05-10. The SHP and Medicaid are in opposite postures on the same drug class in the same state — a cross-jurisdictional contradiction found in no other state in this series.

All coverage claims in this article are verified as of 2026-05-10. NC Medicaid policy can change. The April 14, 2026 PDL Review Panel meeting was the formal ratification venue for the off-cycle reinstatement; coverage is subject to future budget cycles. Check the live PDL at medicaid.ncdhhs.gov/preferred-drug-list and the live PA criteria at nctracks.nc.gov before submitting a PA request.

Pattern #9: double reversal — NC in the 9-state series

Our 50-state Medicaid GLP-1 series has now profiled nine programs. The first eight all reached the same policy outcome — non-coverage for chronic weight management — via different mechanisms. North Carolina is the first state to break that pattern:

NC is the first state in this series to have COVERED the chronic-weight-management indication, TERMINATED it, and then REINSTATED it within a single 16-month window. That makes NC the editorial counter-example to every prior state in the series.

The inverse-Pennsylvania comparison is the clearest structural contrast: Pennsylvania (Pattern #7) covered GLP-1s for weight management from March 2023 through December 31, 2025, then terminated coverage on January 1, 2026 and has not reinstated it. NC and PA share the same October 2025 – January 2026 calendar window for their reversal decisions but reached opposite outcomes: PA terminated and stayed terminated; NC terminated and reinstated within 73 days.

The 16-month on-off-on timeline

The following chronology is anchored to verified primary-source documents. Every date is a documented event, not a projection.

A critical observation: the 73-day gap between October 1 and December 12, 2025 was not a total coverage blackout. Even during that window:

• Wegovy and Zepbound remained covered for FDA-indicated non-weight-loss indications (Wegovy MACE reduction, Wegovy MASH F2/F3, Zepbound moderate-to-severe OSA).
• Members under 21 with previously-approved EPSDT-based prior authorizations were explicitly not end-dated per the Trillium September 11, 2025 notice.
• All GLP-1 coverage for type 2 diabetes (Ozempic, Trulicity, Victoza, Mounjaro, Byetta, and generics) was unaffected throughout.
• The Non-Incretin Mimetics anti-obesity drugs (diethylpropion, phendimetrazine, phentermine as Preferred; orlistat, generic phentermine/topiramate as Non-Preferred) remained on the PDL continuously and were never part of the termination.

The federal anchor: SPA TN 24-0032 and the August 1, 2024 coverage decision

The legal foundation for NC Medicaid’s GLP-1 chronic weight-management coverage is the State Plan Amendment Transmittal #2024-0032, “Coverage of FDA-Approved Weight Loss Drugs,” effective August 1, 2024, signed by Jay Ludlam as NCDHHS Secretary of NC Medicaid (per Ashley Blango, SPA Coordinator) and approved by CMS.

The Background and Summary section of the SPA Signature Request Memorandum states verbatim:

“This SPA will remove weight loss agents as an excluded drug class. Prescription obesity management medications are now playing a role in addressing the obesity epidemic, as they may provide additional weight loss benefits compared to lifestyle modifications alone. Because of the substantial associated weight loss of these medications, there has been an increased uptake of state Medicaid program coverage. Following an approved state plan amendment, NC Medicaid can cover FDA-approved obesity management medications and receive federal match.”

The SPA replaced the prior state plan exclusion list (TN 14-011 for the Categorically Needy version and TN 12-021 for the Medically Needy version). The resulting exclusion list (verbatim, Attachment 3.1-A.1, page 14h) reads:

“(2) The following excluded drugs are not covered:
(a) Agents when used for anorexia or weight gain
(b) Agents when used to promote fertility
(c) Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee
(d) Agents when used for the symptomatic relief of cough and colds. All legend products that contain expectorants or cough suppressants.
(e) All legend vitamins and mineral products, except prenatal vitamins and fluoride.
TN No.: 24-0032   Effective Date: 08/01/2024   Supersedes TN No.: 14-011”

The structural significance: the federal authority at 42 U.S.C. § 1396r-8(d)(2)(A) permits states to exclude “Agents when used for anorexia, weight loss, or weight gain.” NC’s State Plan exclusion list uses the phrase “Agents when used for anorexia or weight gain” — omitting the “weight loss” category. This means NC’s State Plan has never excluded weight-loss agents. TX, NY, FL, IL, OH, PA, and GA have all elected to invoke § 1396r-8(d)(2)(A). NC and California are the two states in this 9-state series that have declined to do so.

The then-NCDHHS Secretary Kody H. Kinsley (architect of the SPA) explained the Medicaid calculus to KFF Health News:

“I spend almost a billion dollars a year on obesity-related diseases. If I can reduce that spend by even 1%, then these drugs are a no-brainer.”

Kinsley also noted that Medicaid’s “generous rebates” made coverage viable for NC Medicaid where it was untenable for the State Health Plan. That rebate differential is central to understanding why the same state reached opposite decisions for two different beneficiary populations in the same 12-month window.

The October 1, 2025 termination: HB 562 and the $319 million shortfall

On September 5, 2025 — 26 days before the effective termination date — NC Medicaid issued a Pharmacy Newsletter announcing the coverage change. The verbatim explanation:

“Given shortfalls in state funding, effective Oct. 1, 2025, coverage for GLP-1s for the treatment of obesity, which is an optional benefit for Medicaid programs, will be discontinued.

NC Medicaid remains committed to the potential of GLP-1s for the treatment of obesity; however, at this time the lack of funding for the program prohibits continued coverage for weight management purposes.

GLP-1s will continue to be covered for the indications of diabetes, reduction in cardiovascular death, heart attack and stroke in obese adults with cardiovascular disease, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and severe obstructive sleep apnea (OSA).”

The September 2025 newsletter’s “What’s Changing” section stated:

“Effective Oct. 1, 2025, Wegovy, Zepbound and Saxenda will be removed from the Preferred Drug List (PDL) as an off-cycle change. Saxenda will no longer be covered for any indication. The Non-Incretin Mimetics class of drugs for treatment of obesity will continue to be managed through the PDL. Drugs in the Preferred status on the PDL include: diethylpropion, phendimetrazine and phentermine. These products do not require prior approval.”

The proximate budget cause: the North Carolina General Assembly’s August 2025 stopgap spending measure (House Bill 562) added $600 million to the Medicaid budget against NCDHHS’s $819 million ask, producing the $319 million shortfall Secretary Sangvai cited as the budget driver for the termination. A subsequent Senate version of HB 562 added another $90 million. Neither version of HB 562 named GLP-1s as a coverage target. The October 2025 termination was a downstream budget-pressure decision, not a legislature-directed policy mandate.

This framing matters: the termination was explicitly attributed to budget constraints and framed as temporary (“at this time the lack of funding… prohibits continued coverage”). NC Medicaid acknowledged the clinical case for coverage even while suspending it — setting up the conditions for reinstatement 73 days later.

The December 12, 2025 reinstatement: the Governor’s directive

On December 19, 2025, NC Medicaid published the bulletin “NC Medicaid to Reinstitute Coverage of GLP-1s for Weight Management,” announcing reinstatement effective December 12. The verbatim operative language:

“In accordance with the Governor’s directive, NC Medicaid coverage for GLP-1s for the treatment of obesity has been reinstated effective Dec. 12, 2025.

Coverage of GLP-1s for Weight Management will revert to the criteria in place as of Sept. 30, 2025, restoring access to medications previously available under the NC Medicaid Outpatient Pharmacy Prior Approval Criteria GLP-1s for Weight Management, effective Aug. 1, 2024.

Wegovy, Zepbound and Saxenda has been added back to the Preferred Drug List (PDL) as an off-cycle change. Wegovy is a Preferred Product. Zepbound and Saxenda are Non-Preferred Products.

These changes will be reviewed in the April PDL panel review meeting.”

NC is the only state in this 9-state series whose GLP-1 chronic weight-management coverage was restored by gubernatorial directive. The mechanism was an off-cycle PDL revision triggered by the Governor’s action — permissible under the NC Medicaid PDL framework when there is “a significant financial impact for the State” or a product-access issue.

The PDL Review Panel’s January 22, 2026 meeting minutes (verified, DRAFT) reproduce the reinstatement language verbatim and confirm that formal ratification will be incorporated into the April 1, 2026 PDL cycle:

“The PDL with recommendations from this meeting will become effective on April 1, 2026. The next PDL panel review meeting will be held on Tuesday April 14, 2026. The PDL Panel meetings occur quarterly in January, April, July and October.”

Current PDL listing: the January 1, 2026 weight management class

The NC Medicaid PDL effective January 1, 2026 (Revised 12.10.2025) carries this header note across every page of the document:

“Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL. See clinical criteria for coverage.”

The operative class header for the weight management class reads (verbatim, PDL lines 2264–2267):

“WEIGHT MANAGEMENT AGENTS
GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimetics)
Plans may not apply additional utilization management or prior authorization criteria to this category
Clinical criteria apply to all drugs in this class”

The “Plans may not apply additional utilization management or prior authorization criteria to this category” notation (the red-text rule) is binding on all five NC Medicaid Standard Plans and all four Tailored Plans, effective January 1, 2026 per the December 8, 2025 NCDHHS bulletin “Utilization Management by Managed Care Plans Aligned with Food and Drug Administration Labeling.” This means the MCOs cannot layer stricter PA criteria on top of the State criteria for this class. If a plan-specific PA form contains stricter thresholds than the State PA criteria document, the State document is operative.

Wegovy’s Preferred status for the chronic-weight-management indication is the single most distinctive PDL finding in the 9-state series. Across the other eight states: PA terminated Wegovy’s weight-management coverage January 1, 2026; NY’s Wegovy DUR pathway is for the FDA MACE indication only; OH’s Metabolic Modifiers class lists Wegovy for MACE and MASH only (not weight management); CA’s Medi-Cal Rx March 2026 re-add is for MASH only; TX, FL, IL, and GA have no Wegovy coverage for weight management at all. NC is the only state in this series whose PDL lists Wegovy as Preferred for the obesity/chronic-weight-management indication as of 2026-05-10.

Note also that Foundayo (LillyDirect tirzepatide direct-to-consumer brand) does not appear on the NC Medicaid PDL. Foundayo is a cash-pay LillyDirect brand that does not bill insurance. PDL status is irrelevant to the Foundayo patient pathway.

PA criteria: PAG Submission 25J7 (Aug 1, 2024, reinstated Dec 12, 2025)

The operative clinical criteria are the NC Medicaid Outpatient Pharmacy Prior Approval Criteria, “GLP1s for Weight Management — Wegovy and Zepbound,” Effective Date August 1, 2024 (PAG Submission 25J7). The December 19, 2025 reinstatement bulletin explicitly reverted to “the criteria in place as of Sept. 30, 2025” — which is the August 1, 2024 document.

Eligible medications

Verbatim from the PA criteria document, page 1:

“Therapeutic Class Code: J8E; J8G
Therapeutic Class Description: ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEPT.AGONIST; ANTI-OBESITY – INCRETIN MIMETICS COMBINATION

Medications
Saxenda® (liraglutide) (12 and over)
Wegovy™ (semaglutide) (12 and over)
Zepbound™ (tirzepatide) (18 and over only)”

Zepbound is limited to adults 18+ under NC Medicaid criteria, aligned with the current FDA tirzepatide chronic-weight-management label (adults only). Saxenda and Wegovy extend to age 12, aligned with their respective FDA pediatric obesity labels.

EPSDT carve-out for members under 21

The PA criteria document (page 1, lines 22–48) explicitly incorporates the federal EPSDT mandate:

“EPSDT Special Provision: Exception to Policy Limitations for Beneficiaries under 21 Years of Age 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]

Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiaries under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination … Service limitations on scope, amount, duration, frequency, location of service, and/or other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider’s documentation shows that the requested service is medically necessary ‘to correct or ameliorate a defect, physical or mental illness, or a condition [health problem]’…”

This EPSDT carve-out was operative even during the 73-day termination window. The Trillium Health Resources September 11, 2025 notice explicitly stated: “Members under 21 years of age previously approved for a GLP-1 for weight management based on federal EPSDT guidelines would not need to have their PA end dated.”

Initial PA criteria (adults and adolescents)

Verbatim from the PA criteria document (pages 1–2, lines 66–108):

“Clinical Coverage
The beneficiary is overweight or obese and is using the requested agent for weight management and ALL of the following:

• Product prescribed must be FDA approved for the indication, age, weight (if applicable) and not exceed dosing limits per the Prescribing Information per the clinical conditions for use.
• The preferred drug, if applicable, which treats the PA indication, is required unless the patient meets the non-preferred PDL PA criteria, including completion of an adequate titration period of 3 to 6 months of the preferred drug. (Failure of the preferred drug is considered to be a drug trial and failure of 3 to 6 months to complete dose titration and determine the side effect profile for the member, unless there is a documented contraindication to the preferred drug. Titration can take up to 6 months for GLP1s.)
• Prescriber must provide the patient’s baseline weight and BMI, to be documented on the PA form, as measured within the past 45 days of the submitted PA.
• The beneficiary is new to therapy or attempting a repeat weight loss course of therapy AND
• ONE of the following:
  • The beneficiary is 18 years of age or over and has ONE of the following:
    • A BMI greater than or equal to 30 kg/m² OR
    • A BMI greater than or equal to 27 kg/m² with at least one weight-related comorbidity/risk factor/complication (i.e. hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia) OR
  • The beneficiary is 12–17 years of age and has ONE of the following:
    • A BMI greater than or equal to the 95th percentile for age and sex OR
    • A BMI greater than or equal to 30 kg/m² OR
    • A BMI greater than or equal to the 85th percentile for age and sex AND at least one severe weight-related comorbidity/risk factor/complication OR
  • The beneficiary is 45 years of age or older with a BMI greater than or equal to 27 kg/m² AND has established cardiovascular disease (CVD) defined as having a history of myocardial infarction, stroke, or symptomatic peripheral disease, to be documented on the PA form. AND
• The beneficiary is currently on and will continue lifestyle modification including structured nutrition and physical activity, unless physical activity is not clinically appropriate at the time GLP1 therapy commences. AND
• The beneficiary will NOT be using the requested agent in combination with another GLP-1 receptor agonist agent AND
• The beneficiary does NOT have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of medullary thyroid cancer or multiple endocrine neoplasia type II.”

Renewal criteria — 5% threshold and no lifetime cap

Verbatim from the PA criteria document (page 2, lines 111–134):

“Renewal Criteria
• The beneficiary has been previously approved for the requested agent through Medicaid’s Prior Authorization process AND
• The beneficiary is using the requested agent for weight management and ALL of the following criteria have been met:
  • The beneficiary is continuing a current weight loss course of therapy AND
  • Adults: the patient has lost a total of 5% of pretreatment weight and maintains the 5% weight loss. Baseline and current weight are to be provided on the PA form. OR
  • Adolescents: (>12 to <18 years) have had >4% reduction in baseline BMI and maintain the weight loss. Baseline and current weight are to be provided on the PA form. OR
  • Adults or Adolescents have a documented weight loss that is deemed to be a significant reduction from BMI per the prescriber and the weight loss is maintained, yet the 5% (for adults) and 4% (for adolescents) is not met. Rationale, baseline, and current weight are to be provided on the PA form. AND
• The beneficiary is currently on and will continue lifestyle modification including structured nutrition and physical activity AND
• The beneficiary will not be using the requested agent in combination with another GLP-1 receptor agonist agent AND
• The beneficiary does NOT have any FDA-labeled contraindications to the requested agent

Duration of Approval
6 months for the initial approval, 12 months for renewal; no limit on the number of renewals that may be provided.”

Two NC-specific advantages relative to other states in the series deserve emphasis:

• No lifetime treatment cap. New York caps Wegovy DUR at two treatment attempts per lifetime. NC has no such cap — “no limit on the number of renewals that may be provided.”
• Clinical rationale escape valve. If a patient has documented significant weight loss that the prescriber deems clinically meaningful but that falls below the 5% (adult) or 4% (adolescent) threshold, the prescriber can provide a written rationale and still obtain a renewal. Pennsylvania and Ohio do not publish this flexibility; NC’s criteria are more patient-centered on renewal.

Quantity limits

Verbatim (page 2, lines 136–140):

“Quantity Limits
• Wegovy 3 mL/28 days. Titration doses are 2 mL/28 days.
• Saxenda 15 mL/30 days
• Zepbound 2 mL/28 days”

These quantity limits match FDA-label maximum dosing for each drug. NC Medicaid does not impose stricter quantity limits than the FDA labels for the chronic-weight-management indication.

Wegovy for cardioprotection (FDA MACE indication)

In addition to the standard chronic-weight-management pathway, the PA criteria (page 3, lines 142–163) include a dedicated pathway for Wegovy’s FDA-approved cardiovascular risk-reduction indication. Verbatim:

“Wegovy
1. For the indication of cardioprotection:
• Beneficiary must have a documented baseline BMI prior to beginning GLP-1 therapy > 27 kg/m² AND
• Beneficiary is ≥ 45 years of age AND
• Beneficiary must have established cardiovascular disease (CVD) defined as having a history of myocardial infarction, stroke, or symptomatic peripheral arterial disease. AND
• Beneficiary must not have a personal or family history of medullary thyroid carcinoma. AND
• Beneficiary must not have multiple endocrine neoplasia syndrome type 2. AND
• Beneficiary must have at least 3 months of lifestyle modifications prior to starting Wegovy. AND
• Beneficiary should be using Wegovy in combination with a reduced calorie diet and increased physical activity.
• The beneficiary is currently on and will continue lifestyle modification including structured nutrition and physical activity, unless physical activity is not clinically appropriate at the time GLP1 therapy commences”

The NC age floor for this pathway is 45 years. Pennsylvania and Ohio require age ≥ 18. The 45-year minimum is a meaningful access barrier for adults aged 18–44 who have established CVD and overweight (BMI 27–29.9) — those patients must route through the standard chronic-weight-management pathway with CVD as the qualifying comorbidity rather than the dedicated cardioprotection pathway.

NC does NOT exclude T2D patients from the cardioprotection pathway, unlike Ohio (which explicitly requires A1C < 6.5% and excludes T1D and T2D patients). NC is FDA-label-aligned on this point — the Wegovy MACE label has no diabetes-status exclusion.

NC requires 3 months of prior lifestyle modifications for the cardioprotection pathway — stricter than the standard weight-management pathway, which only requires concurrent lifestyle modifications.

Wegovy for MASH: F1, F2, and F3 fibrosis — broader than the FDA label

The PA criteria (pages 3–4, lines 164–207) include a pathway for Wegovy in noncirrhotic NASH/MASH:

“2. For the indication of noncirrhotic nonalcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH)
• The beneficiary has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH) AND ALL of the following: (medical records required)
  • The beneficiary has stage F1, F2, or F3 fibrosis as confirmed by BOTH of the following (prior to therapy with the requested agent):
    • A FIB-4 score consistent with stage F1, F2, or F3 fibrosis adjusted for age AND
    • The beneficiary has ONE of the following: A liver biopsy OR Vibration-controlled transient elastography (VCTE) (such as FibroScan) OR Enhanced liver fibrosis (ELF) score OR Magnetic resonance elastography (MRE) OR FibroSure AND
  • The requested agent is Wegovy AND
  • The beneficiary is an adult (18 years of age or over) AND
  • The beneficiary has ONE of the following: A baseline BMI prior to beginning therapy of greater than 25 kg/m² OR A baseline BMI prior to beginning therapy of greater than 23 kg/m² if the beneficiary is of South Asian, Southeast Asian, or East Asian descent AND
  • The beneficiary has ONE of the following: The beneficiary’s sex is female then the beneficiary’s alcohol consumption is less than 20 grams/day … OR The beneficiary’s sex is male then the beneficiary’s alcohol consumption is less than 30 grams/day … AND
  • The beneficiary is being monitored for development of and/or treated for any comorbid conditions (e.g., cardiovascular disease, diabetes, dyslipidemia, hypertension) AND
  • The beneficiary does NOT have ANY of the following: Decompensated cirrhosis; Moderate to severe hepatic impairment (Child-Pugh Class B or C); Any other liver disease (e.g., Wilson’s disease, hepatocellular carcinoma, hepatitis)”

The F1 inclusion requires explicit clinical context. The FDA Wegovy MASH supplemental label (approved March 2024) is for moderate-to-advanced fibrosis, i.e., F2/F3. NC’s PA criteria explicitly include F1 — early-stage fibrosis — making NC’s MASH pathway broader than the FDA label and broader than PA and Ohio (both F2/F3 only). This may reflect deliberate NC-specific broader-than-FDA-label coverage policy or may be an editorial artifact of the August 2024 drafting.

NC is also the only state in this series that includes FibroSure (a serum fibrosis panel) as a permissible biomarker — the other states accept FibroScan VCTE, MRE, or liver biopsy but not FibroSure.

Zepbound for moderate-to-severe OSA: BMI > 30 — the most-permissive threshold in the series

Verbatim from the PA criteria (page 5, lines 230–257):

“Zepbound
1. For the indication of Moderate to Severe Sleep Apnea: The beneficiary is using the requested agent for moderate to severe obstructive sleep apnea (OSA) in adults with obesity and ALL of the following:

• Beneficiary must have a documented baseline BMI prior to beginning therapy of > 30 kg/m² AND
• The beneficiary is an adult (18 years of age or over)
• Product prescribed must be FDA approved for the indication, age, weight (if applicable) and not exceed dosing limits per the Prescribing Information per the clinical conditions for use. AND
• The beneficiary is currently on and will continue lifestyle modification including structured nutrition and physical activity, unless physical activity is not clinically appropriate at the time GLP1 therapy commences. AND
• The beneficiary will NOT be using the requested agent in combination with another GLP-1 receptor agonist agent AND
• The beneficiary does NOT have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of medullary thyroid cancer or multiple endocrine neoplasia type II. AND
• Documentation confirming that sleep apnea testing was performed and moderate to severe sleep apnea was diagnosed must be submitted with the prior approval request. AND
• The beneficiary should have been instructed on sleep hygiene modifications before beginning Zepbound (for example, sleep positioning to avoid a non-supine position, avoidance of alcohol and stimulants before bed)”

NC’s OSA pathway requires BMI > 30 — FDA-label-aligned and the most permissive threshold in the series (PA requires BMI ≥ 35 for the same indication). NC does NOT require a PAP-trial-and-fail: PA mandates either documented PAP adherence (4 hours/night, 70% of nights, 30 days) or documented PAP intolerance. NC simply requires documented OSA diagnosis and evidence of sleep hygiene counseling. This is a structural access advantage for NC Medicaid patients who are not PAP candidates or who have not yet completed a PAP trial.

One YMYL caution for NC patients with UnitedHealthcare Community Plan (UHC): the UHC NC GLP-1 PA form (effective 10/01/2025) specifies BMI > 40 for the Zepbound OSA pathway — a direct contradiction of the State criteria (BMI > 30). The December 8, 2025 NCDHHS “Plans may not apply additional UM” binding directive forbids UHC from applying that stricter threshold. If a prescriber is told by UHC that BMI > 40 is required, cite the State PA criteria document (PAG 25J7, page 5) and escalate to NC OAH if needed. The State criteria are operative; UHC’s form appears to be an out-of-date plan-specific form that does not reflect the current binding State standard.

T2D coverage is a separate class — unaffected by the on-off-on cycle

The October 2025 termination and December 2025 reinstatement applied exclusively to the “WEIGHT MANAGEMENT AGENTS — GLP-1 Receptor Agonists indicated for the treatment of obesity” PDL class. The separate “GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes” class was unaffected throughout.

The T2D class on the January 1, 2026 PDL (verbatim class header, lines 1245–1247):

“GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes
Plans may not apply additional utilization management or prior authorization criteria to this category
Clinical criteria apply to all drugs in this class”

A patient with both T2D and obesity can have a T2D PA for Ozempic AND a separate chronic-weight-management PA for Wegovy — but cannot use two GLP-1 receptor agonists simultaneously (the no-combination-GLP-1 rule applies to both classes).

The NC State Health Plan: opposite posture in the same state

The NC State Health Plan (SHP) is NOT North Carolina Medicaid. These are two entirely separate insurance programs with separate boards, separate budgets, and separate coverage decisions. The cross-jurisdictional contradiction is real and documented, but the two programs are legally and operationally distinct.

The SHP is a separate insurance program for approximately 740,000 state employees, retirees, lawmakers, university and community college personnel, and dependents. It is administered by the State Health Plan Board of Trustees with the State Treasurer as Chair (Dale Folwell served 2017–2025; Brad Briner succeeded Folwell effective January 2025). The SHP’s pharmacy benefit is administered by CVS Caremark.

Per the NC Treasurer’s April 22, 2024 press release:

• The SHP Board voted 4-3 in January 2024 to end GLP-1 coverage for weight loss, effective April 1, 2024.
• At the time of termination, 23,000+ SHP members were using GLP-1 medications.
• The net cost was over $800 per member per month after rebates.
• Projected 2024 spending would have exceeded $170 million; the six-year projection was more than $1 billion.
• The SHP faced a five-year budget gap of $4.2 billion, with the state legislature allocating $240 million less than requested.

KFF Health News quoted the then-Treasurer:

“We are trying everything we can to be able to provide these drugs to the members of the Plan.” (Folwell, expressing concern about “price-gouging by the manufacturers.”)

KFF Health News summarized the cross-jurisdictional contrast verbatim:

“North Carolina’s State Health Plan eliminated coverage for GLP-1 agonist medications for weight loss beginning in April 2024, while continuing to cover these drugs for Type 2 diabetes management. However, North Carolina’s Medicaid program began covering the drugs for weight loss in August 2024.”

The irony is structural: NC Medicaid expansion (effective December 1, 2023) added approximately 600,000 newly eligible adults under 138% FPL. Eight months later, the August 2024 SPA added GLP-1 chronic weight-management coverage for that same population. The combined effect: NC’s low-income adults gained access to the same drugs that the SHP had just terminated for NC’s state employees (generally higher-income). Secretary Kinsley’s explanation: Medicaid’s federal rebate structure made the math work for Medicaid where it did not for the SHP.

The SHP termination remains in effect as of 2026-05-10. The verifier did not locate a primary-source SHP reinstatement notice. State employees seeking weight-loss GLP-1 coverage should contact the SHP directly at shpnc.gov.

NC Medicaid expansion population context

North Carolina Medicaid serves approximately 3.1 million enrollees (top-9 nationally by enrollment) following the December 1, 2023 launch of Medicaid expansion. Expansion added approximately 600,000 newly eligible adults under 138% of FPL (ages 19–64); 450,000 were enrolled by May 2024. The benefit is administered by the North Carolina Department of Health and Human Services (NCDHHS) Division of Health Benefits (DHB).

Coverage is delivered through two program structures:

• NC Medicaid Managed Care (Standard Plans) — five plans serving the general Medicaid population: AmeriHealth Caritas North Carolina, Carolina Complete Health, Healthy Blue of North Carolina, UnitedHealthcare Community Plan of North Carolina, and WellCare of North Carolina.
• NC Medicaid Tailored Plans (LME-MCO successor plans)— four plans (Alliance Health, Partners Health Management, Trillium Health Resources, Vaya Health), launched July 1, 2024, serving approximately 143,000 members with serious mental illness, severe substance use disorders, intellectual/developmental disabilities, or traumatic brain injuries. These plans deliver physical health, pharmacy, AND behavioral health benefits under one plan.

A small NC Medicaid Direct (fee-for-service) segment remains for members not yet enrolled in managed care. FFS pharmacy claims were processed through NCTracks until May 2, 2026, when Prime Therapeutics State Government Solutions LLC assumed the Pharmacy Benefit Administrator role.

PBM structure: plan-specific PBMs + May 2026 Prime Therapeutics transition

NC Medicaid operates a plan-specific PBM model: each Standard Plan and Tailored Plan contracts with its own PBM. Verified plan PBMs include:

• AmeriHealth Caritas NC — PerformRx (verified via the AmeriHealth Caritas NC GLP-1 PA form fax line 1-877-234-4274)
• Trillium Health Resources — PerformRx (verified via the Tailored Plan GLP-1 PA structure)
• UnitedHealthcare Community Plan of NC — Optum Rx (verified via UHC NC GLP-1 PA form fax line 1-866-940-7328)
• NC Medicaid Direct (FFS) — Prime Therapeutics State Government Solutions LLC, effective May 2, 2026 (previously NCTracks legacy adjudication)

The May 2, 2026 Prime Therapeutics transition affects only NC Medicaid Direct POS pharmacy claims. Per the NC Medicaid May 4, 2026 bulletin:

“NCDHHS has contracted Prime Therapeutics State Government Solutions LLC (Prime Therapeutics) to support pharmacy benefit operations.” “[E]ffective May 2, 2026.” “This transition only applies to NC Medicaid Direct POS pharmacy claims and does not apply to pharmacy claims from NC Medicaid Managed Care Plans.”

The binding “Plans may not apply additional UM” rule (from the December 8, 2025 NCDHHS bulletin) means that despite the plan-specific PBM fragmentation, all five Standard Plans and all four Tailored Plans must process GLP-1 weight-management PAs under the State-level criteria. This is operationally similar to PA (statewide PDL binding MCOs + plan-specific PBMs), and structurally different from Ohio’s centralized Gainwell SPBM model (where plan-level divergence is structurally impossible).

Coverage scope: who qualifies and who is excluded

The inverse-Pennsylvania comparison: same window, opposite outcomes

Pennsylvania and North Carolina are the two most instructive comparison states in the 9-state series because their reversal decisions fell in the same calendar window — October 2025 to January 2026 — and reached opposite outcomes.

The inverse-Pennsylvania framing is not an editorial judgment about which approach is better — it is a documented structural contrast anchored to primary sources in both states. PA and NC made the decision to terminate coverage in the same broad budget-pressure window. NC reversed that decision within 73 days; PA has not.

Patient action steps: submitting a GLP-1 PA request in NC Medicaid

Step 1: Confirm current eligibility

Verify your current NC Medicaid plan membership. Standard Plan or Tailored Plan membership determines which PA form and contact number to use. Your member ID card will identify your plan. For NC Medicaid Direct (FFS), claims now process through Prime Therapeutics (effective May 2, 2026).

Step 2: Start with Wegovy (the Preferred drug)

Unless you have a documented contraindication to Wegovy (history of medullary thyroid carcinoma, MEN-2, pregnancy, severe GI hypersensitivity), your prescriber should submit a PA for Wegovy first. Saxenda and Zepbound require trial-and-failure of Wegovy or a documented contraindication.

Step 3: Documentation the PA form requires

• Current weight and BMI measured within the past 45 days (the PA form requires this specific recency window).
• Documentation of qualifying BMI threshold or comorbidity (diagnosis codes for T2D, HTN, dyslipidemia, OSA, CVD as applicable).
• Statement of current lifestyle modification (structured nutrition and physical activity program) or clinical explanation for why physical activity is not appropriate.
• Confirmation that the patient is not currently using another GLP-1 receptor agonist.
• For the cardioprotection pathway: documentation of established CVD (prior MI, stroke, or symptomatic PAD) + at least 3 months of prior lifestyle modifications.
• For the MASH pathway: FIB-4 score + biopsy/VCTE/ELF/MRE/FibroSure report + alcohol-use documentation.
• For the OSA pathway (Zepbound): sleep apnea diagnostic test report (AHI score) + sleep hygiene counseling documentation.

Step 4: Submit PA

PA requests go to your plan’s PBM. AmeriHealth Caritas NC uses PerformRx (fax 1-877-234-4274; call 1-866-885-1406). UHC Community Plan uses Optum Rx (fax 1-866-940-7328; call 1-855-258-1593). Other plans use their own PBM portals. NC Medicaid Direct FFS claims route through Prime Therapeutics (effective May 2, 2026). Live PA criteria and forms are at nctracks.nc.gov.

Appealing a PA denial: NC Office of Administrative Hearings

If your PA is denied, NC Medicaid law provides a structured appeal pathway through the NC Office of Administrative Hearings (OAH). The OAH defines an adverse decision as:

“[A]n adverse decision [is] a determination by the Department of Health and Human Services to deny, terminate, suspend, or reduce a Medicaid service or an authorization.”

Filing deadlines differ by plan type:

• NC Medicaid Direct (FFS): “Return the completed Hearing Request Form to the Office of Administrative Hearings within 30 days of the date the adverse decision was mailed.”
• NC Medicaid Managed Care (Standard / Tailored Plans): “Return the completed State Fair Hearing Request Form to the Office of Administrative Hearings and the managed care organization within 120 days of the date the Notice of Resolution was mailed.”

The MCO-level appeal deadline (120 days) is substantially more generous than the FFS deadline (30 days). Managed-care beneficiaries have an internal MCO appeal step before reaching OAH.

Once a request is filed, mediation typically begins within 25 days. If mediation does not resolve the dispute, an Administrative Law Judge (ALJ) hearing follows:

“OAH shall schedule and hear contested Medicaid cases within 55 days of submission of a request for appeal.”

The burden of proof rests on the appellant:

“The testimony and/or documentation you present must show that the department made a mistake denying or modifying your Medicaid services.”

PA denials that are appealed successfully typically involve one of three scenarios: (1) the PA criteria were misapplied (e.g., the plan used an incorrect BMI threshold such as UHC’s BMI > 40 for Zepbound OSA vs the State’s BMI > 30); (2) the documentation was complete but not recognized by the plan’s automated system; or (3) the prescriber submits an EPSDT-based medical necessity argument for a member under 21. The ALJ cannot override NC Medicaid policy — but can correct an erroneous application of the existing criteria.

File appeals at: oah.nc.gov.

KFF January 2026 context: the 13-state positive-coverage group

KFF (January 2026) classifies NC as one of 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service as of January 2026. KFF’s verbatim classification:

“North Carolina eliminated GLP-1 coverage beginning October 2025 due to a budget stalemate in the legislature, but coverage was reinstated in December 2025.”

Of the 16 states that KFF identified as covering GLP-1s for obesity as of October 2025, four states eliminated coverage (California, New Hampshire, Pennsylvania, and South Carolina), leaving 13 states with coverage as of January 2026. NC is the only one of those 13 that completed a full on-off-on cycle within a single calendar year and was reinstated by gubernatorial directive.

Related research

• GLP-1 insurance coverage: Medicare, Medicaid, and commercial plans — full 9-state taxonomy — North Carolina is the counter-example to the 8-state exclusion cluster; the only state in the 9-state series where Wegovy is Preferred for the chronic-weight-management indication.
• Pennsylvania Medicaid GLP-1 coverage (2026): the inverse-NC pattern — covered 34 months then terminated January 1, 2026 and stayed terminated; PA is the structural mirror-image of NC’s double reversal.
• California Medi-Cal GLP-1 coverage (2026): one-direction reversal (MASH-only) — the closest structural analogue: budget-driven reversal followed by partial reinstatement. NC differs: NC reinstated for the full chronic-weight-management indication (not just MASH) and by gubernatorial directive (not P&T action).
• Ohio Medicaid GLP-1 coverage (2026): triple-anchored exclusion + January 2026 Wegovy MACE/MASH carve-back-in — Ohio’s Jan 7, 2026 Metabolic Modifiers class (Wegovy for non-obesity indications only) is narrower than NC’s full chronic-weight-management coverage; the BMI ≥ 27 OSA threshold (PA’s BMI ≥ 35) vs NC’s BMI > 30 threshold is the most direct OSA coverage comparison.
• Florida Medicaid GLP-1 coverage (2026): silent exclusion by PDL absence — Florida is the structural opposite of NC: no active coverage, no MACE or MASH carve-back-in, exclusion operationalized solely by PDL absence. NC’s reinstatement provides a policy template Florida has not followed.
• GLP-1 insurance dropped coverage appeal playbook — four-phase appeal logic (internal, external review, cash-pay bridge, brand switch) with NC OAH State Fair Hearing guidance for NC Medicaid managed-care denials.
• GLP-1 medication list: full reference (every FDA-approved drug)
• Wegovy alternatives for weight management — NC is the only state Medicaid program in the 9-state series where Wegovy is Preferred for chronic weight management; Saxenda and Zepbound are the step-therapy Non-Preferred alternatives.
• New Jersey Medicaid GLP-1 coverage (2026): dual-authority explicit exclusion — NJ is the structural inverse of NC for the state-plan vs. state-employee-plan cross-coverage contradiction. In NC, Medicaid covers GLP-1s for weight loss (Wegovy Preferred since December 2025 reinstatement) while the NC State Health Plan (SHP) terminated coverage in April 2024 (termination remains in effect). In NJ, the SHBP state-employee plan covers non-diabetic GLP-1s for weight loss ($45/$125 copay tier, effective November 1, 2025) while NJ FamilyCare Medicaid categorically excludes them. Both cross-jurisdictional contradictions are documented by primary source.
• Tennessee Medicaid (TennCare) GLP-1 coverage (2026): Pattern #13 — positive-coverage expansion from prior categorical-exclusion baseline — TN (Anchor #13) is the companion positive-coverage state alongside NC (Anchor #9). NC was a double-reversal (coverage briefly terminated October 2025, reinstated December 2025) within an ongoing framework. TN expanded FROM a categorical-exclusion baseline effective August 1, 2025. Both states now list Wegovy as Preferred; TN additionally lists Zepbound as Preferred in a dedicated “GLP-1 Weight Management Agents” class. TN’s state-employee plan (Caremark) does not cover Zepbound — the inverse of NC’s asymmetry (NC SHP terminated; NC Medicaid covers).